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Rectum 0.34 0.48 0.46 0.37 -0.06 -0.06 -0.06 -0.04 
Sigmoid 1.39 0.96 0.72 0.66 0.44 0.22 0.18 0.17 
Anus 0.81 0.99 0.54 0.68 -0.07 -0.13 -0.09 -0.09 
Femoral 
heads 1.66 1.49 1.45 1.47 -0.44 -0.4 -0.41 0.43 
Penile bulb 0.43 0.33 0.27 0.39 -0.02 -0.04 -0.03 -0.11 
 
A SD of 0.5-1 cm was measured for the anus with the largest 
discrepancies for its proximal part. A good correlation between 
delineations was observed for the rectum with a SD of 0.3-0.5 cm with 
the largest discrepancy for its distal part. The sigmoid had a SD of 0.6-
1.4 cm between observers with the largest discrepanties for its distal 
part. A SD of 1.4-1.7 cm was observed between delineation of the 
femoral heads with largest discrepanties for their distal parts. A small 
SD of 0.3-0.4 cm was obtained for the penile bulb. 
Conclusions: Given SD < 0.5 cm for the rectum and penile bulb, the 
suggested guidelines were easy to follow and found sufficient in 
delineation of these OARs. Larger SD in delineation of the anus, 
sigmoid and femoral heads appeared to result from incomplete 
guidelines for those OARs. Stricter guidelines with better definition of 
OAR anatomical borders-particuly the proximal borders of the anus 
and distal borders of sigmoid and femoral heads- are needed.  
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Purpose/Objective: New treatments are being introduced in the 
treatment of locally advanced esophageal cancer. Some, such as 
trastuzumab, can potentially increase cardiotoxicity. The purpose of 
this study was to model cardiac toxicity using an empirical normal 
tissue complication probability (NTCP) model in patients with 
esophageal cancer treated in part with radiotherapy. 
Materials and Methods: Cardiactoxicity as measured by Common 
Toxicity Criteria Adverse Events (CTCAE) v3.0 and Radiation Therapy 
Oncology Group (RTOG) toxicity grading scale was identified by 
retrospective chart review. The probability of cardiac toxicity as a 
function of absorbed dose in a partial volume was modeled by the 
method of Lyman, by converting the dose volume histograms into an 
equivalent fractional volume receiving the maximum dose in the DVH, 
using the effective volume method of Kutcher and Burman. The 
parameters in this model (D50, slope mand volume exponent n) were 
determined by maximum likelihood estimation. Doses prescribed in 
fractional doses other than 1.8 Gy were converted to equivalent dose 
in 1.8 Gy fractions assuming an α/β ratio of 1.4 Gy, determined from 
this data set by intercomparing combinations of total dose and dose 
per fraction giving similar levels of toxicity. 
Results: From 6/02 to 4/12, 150 patients (113 male and 37 female) 
with locally advanced esophageal cancer undergoing pre-operative or 
definitive CRT at 2 NCI Comprehensive Cancer Centers form the basis 
of this analysis. The mean radiotherapy dose was 4912 (range:3000-
5940) cGy. Chemotherapy was at the discretion of the treating 
medical oncologist. Thirty-four (23%) developed a cardiac toxicity 
with 10 being symptomatic (> grade 3 toxicity). The mean time to any 
toxicity was 8 (range:1-29) months. Cardiac toxicity types were 
Pericardial effusion-27; Heart failure- 2, Atrial Fibrillation-1, 
Cardiomegaly-1, Ischemia-1, MI-1, Sick sinus syndrome-1. The 
maximum likelihood fit of the Lyman model parameters to patients 
with cardiac symptoms were n = 0.4 m= 0.34, TD50=54.2 Gy for men 
and TD50=41.8 Gy for women, p=0.027.  
Conclusions: These results are comparable to earlier reports. What is 
not known, however, is the use of a single toxicity endpoint rather 
than combined endpoints. The pathophysiologic etiology of pericardial 
effusion most likely is not the same as heart failure, one being an 
effect on the pericardium while the other an effect on the cardiac 
myocytes. Further work is needed to clarify the dose resulting in 
toxicity to each cardiac structure necessary to result in cardiactoxicity 
and why we see a difference between men and women.  
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Purpose/Objective: Several studies have shown that breast cancer 
treatment may increase the risk of cardiovascular disease after ten or 
more years. However, most reports are based on older treatment 
regimens. It is not known whether more contemporary radiation 
techniques are associated with excess cardiovascular disease. In 
addition, it is not clear whether current chemotherapeutic regimens, 
especially regimens containing anthracyclines, increase the risk of 
cardiovascular disease in breast cancer survivors. 
The aim of this study is to assess the effect of radiotherapy and 
chemotherapy for breast cancer on cardiovascular morbidity and 
mortality. 
Materials and Methods: We have constructed a large population-
based cohort of patients diagnosed with invasive breast cancer 
between 1989 and 2004 (n=93,630). Information on patient 
characteristics, primary and secondary malignancies, and basic 
treatment information (e.g. type of surgery, radiotherapy yes/no, 
chemotherapy yes/no) were provided by the Netherlands Cancer 
Registry. Detailed treatment information was collected through 
electronic files from radiotherapy institutes, trials, and regional 
studies. Date and cause of death were acquired through linkage with 
the Central Bureau for Genealogy and Statistics Netherlands, 
respectively, until January 2010. Data on cardiovascular morbidity 
were acquired through linkage with two registries: the Hospital 
Discharge Registry (LMR) and the Cardiac Interventions Registry (BHN). 
Results: Of the initial 93,630 patients, 69,123 survived at least five 
years after breast cancer diagnosis. The median follow-up of five-year 
survivors was 9.7 years (range 5-21 years).  
We distinguished four mutually exclusive treatment categories: 
surgery only (33%), radiotherapy with or without surgery (46%), 
radiotherapy and chemotherapy with or without surgery (15%), and 
chemotherapy with or without surgery (6%). 52% of the patients 
treated with radiotherapy were irradiated for left-sided breast 
cancer. Due to the anatomical position of the heart, the radiation-
dose to the heart is higher during left-sided radiotherapy than during 
right-sided radiotherapy. 
At the PREVENT meeting, results will be presented on the evaluation 
of mortality rates in comparison with the general population. 
Secondly, we will present comparisons of cardiovascular mortality 
rates and incidence of different cardiovascular diseases between the 
above stated treatment categories, and more specifically by type of 
chemotherapeutic, radiation field, and laterality. 
Conclusions: Based on our results, conclusions will be drawn with 
respect to the effects of modern radiotherapy regimens and specific 
chemotherapeutics for breast cancer.  
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Purpose/Objective: Radiation-induced heart disease (RIHD) is a long-
term side effect of radiotherapy of intrathoracic and chest wall 
tumors when radiation fields encompass all or part of the heart. 
Tocotrienols are forms of vitamin E with potent radioprotective 
properties. This study investigates the effects of pre-treatment and 
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post-treatment with tocotrienols in a rat model of local heart 
irradiation. 
Materials and Methods: Male Sprague-Dawley rats received localized 
image-guided X-ray irradiation of the heart with a single dose of 21 
Gy. Groups of animals received a tocotrienol-enriched oral 
formulation 24 hours before irradiation, or in combination with 
pentoxifylline (PTX) starting 3 months after irradiation. At 6 months 
after irradiation, cardiac function and tissue structure were measured 
with echocardiography and histopathology. At time points from 6 
hours to 9 months after irradiation, left ventricular molecular changes 
were examined with real-time PCR and Western-Blots. In addition, 
mitochondria were isolated from left ventricular tissue samples to 
examine mitochondrial membrane potential, mitochondrial transition 
pore activity, and respiration. 
Results: Local heart irradiation caused long term changes in cardiac 
function and structure, coinciding with changes in the expression of 
mediators of the epidermal growth factor receptor (EGFR) pathway, 
and changes in mitochondrial membrane properties and respiration. 
Pretreatment of rats with tocotrienols prevented these effects of 
radiation. Unexpectedly, the late treatment with PTX caused 
bradycardia and arrhythmia in irradiated animals. This adverse event 
was not prevented when tocotrienols were added to the PTX 
treatment. On the other hand, addition of tocotrienols reduced 
cardiac numbers of macrophages and mast cells and enhanced left 
ventricular gene expression of the EGFR mediator neuregulin-1.  
Conclusions: These studies suggest that tocotrienols may be potent 
protectors against cardiac radiation toxicity. Further studies should 
address the effects of tocotrienols when administered after 
irradiation, alone or in combination with other potential mitigators.  
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Purpose/Objective: The radiation dose that can be delivered to 
thoracic tumors is limited by the risk of radiation-induced lung 
toxicity (RILT). ACE-inhibition has been shown to ameliorate RILT in 
rats although the exact mechanism is not elucidated (1). Recently, we 
found that pulmonary vascular remodeling plays an important role in 
the development of RILT in rats resulting in pulmonary hypertension, 
right ventricle hypertrophy and eventually to cardio-pulmonary 
dysfunction (2). We hypothesized that the protective effect of ACE-
inhibition might be due to reduced vascular remodeling and 
pulmonary hypertension. Therefore, in this study we investigated if 
ACE-inhibition ameliorates early radiation-induced cardio-pulmonary 
dysfunction by protection of pulmonary vascular remodeling. 
Materials and Methods: To elucidate the exact protective mechanism 
of ACE-inhibition on early radiation-induced cardio-pulmonary 
function loss rats' lungs, heart or heart and lung were irradiated to 20 
Gy using high-precision proton beams. Captopril was administered in 
the drinking water immediately after irradiation. Cardio-pulmonary 
performance was assessed in the irradiated rats (± captopril) using 
biweekly breathing rate measurements. At 8 weeks post-irradiation, 
when early radiation-induced cardio-pulmonary dysfunction peaks (2), 
left- and right-sided cardiac hemodynamics were measured, CT scans 
and histopathology were analyzed. 
Results: At 8 weeks post-irradiation breathing rate measurements 
showed that captopril significantly improved the rats' cardiac/ 
pulmonary function, but only in the rats where the heart was included 
in the radiation field. Consistently, CT scans showed improvement of 
pulmonary density/structure by captopril only in the heart-irradiated 
groups. 
This protective effect could not be explained by protection of the 
pulmonary vasculature or pulmonary artery pressure changes, which 
were equally damaged with or without captopril. Interestingly, 
besides decreasing the presence of pleural and pericardial effusion, 
left ventricle hemodynamic measurements showed better cardiac 
function parameters in the captopril treated rats. Next to that, 
captopril treatment reduced perivascular fibrosis in the irradiated 
hearts.  
Conclusions: Captopril ameliorates early radiation-induced cardio-
pulmonary dysfunction by reducing acute heart damage and 
consequentially reduces excess RILT caused by inclusion of the heart 
in the irradiation field (3). ACE-inhibition may be a promising strategy 
to reduce early cardio-pulmonary complications induced by 
radiotherapy to the thoracic area in patients receiving a dose to the 
heart.  
 (1) Ghosh et al. Int J Radiat Oncol Biol Phys 2009 
(2) Ghobadi et al. Thorax 2011 
(3) van Luijk et al. Cancer Res 2005 
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Purpose/Objective: This study describes a new treatment verification 
system, based on electronic portal imaging device (EPID) images, for 
HDR brachytherapy. The phantom study incorporates verification of 
both source position and dose as the brachytherapy treatment plan is 
delivered, identifying the potential for real time identification of 
incorrect dose to patients. 
Materials and Methods: An a-Si EPID (IAS11-19, Varian Medical 
Systems,Palo Alto, CA, USA) was used for all measurements. Response 
characteristics of the EPID were determined for use with an Ir-192 
HDR brachytherapy source, including linearity, reproducibility, 
variation in exposure time, image acquisition time,photon energy 
dependence and source position determination in three dimensions.A 
treatment plan was delivered to the phantom and for each dwell 
position in the delivered plan, planar EPID dose distributions were 
compared with the TPS calculated at the same plane. 
Results: Analysis of the EPID images containing the source response 
distribution, yielded the location of the source to better than ± 1mm 
for coordinates parallel to the plane of the EPID at source-to-detector 
distances up to 200mm. The source distance from the EPID surface 
could be determined to within ± 1.5 mm. The comparison of TPS and 
measured dose at a plane 100mm from the brachytherapy source 
agreed to within ± 2% for a 100 x 100 mm region of the EPID plane 
centered at the source (x,y)coordinates, and agreed to within ± 7% 
across the entire EPID panel (300x400mm). Delivery of an erroneous 
treatment plan with missing or incorrectly located dwell positions was 
easily identifiable with this system. 
Conclusions: This is the first system, to our knowledge, providing a 
check of both source position and dwell time during dose delivery. 
The EPID images are sensitive enough to reveal clinically relevant 
source position and dwell time errors. We have established a proof-of-
principle that an EPID can be used for treatment verification in HDR 
brachytherapy.  
 
OC-0263   
HDR brachytherapy dosimetric predictors of biochemical control of 
prostate cancer 
P. Hoskin1, A. Rojas1, P. Ostler1, R. Hughes1, L. Bryant1, G. Lowe1 
1Mount Vernon Hospital, Cancer Centre, Northwood Middlesex, United 
Kingdom  
 
Purpose/Objective: To correlate the dose-volume parameters D90 (Gy) 
and V100 (%) (i.e. minimum dose to 90% of the prostate volume and 
volume that received 100% of the prescribed iso-dose, respectively) 
with biochemical control in patients with advanced prostate cancer 
treated with external beam radiotherapy (EBRT) followed by a boost 
of high-dose rate brachytherapy (HDR-BT). 
Materials and Methods: 108 patients, participating in a randomised 
trial of EBRT± HDR-BT, received EBRT to 35.75 Gy in 13 fractions 
followed by HDR-BT of 2 x 8.5 Gy. Kaplan-Meier freedom-from-
biochemical relapse (FFbR) rates were obtained by stratifying the data 
by those whose D90 and V100 were at or above and below the first (Q1), 
second (Q2) and third (Q3) quartile. Differences between groups were 
compared using the log-rank test. Univariate and multivariate hazard 
ratios for D90 and V100 and other co-variates (prostate specific antigen 
(PSA), androgen deprivation therapy (ADT)) were obtained using Cox's 
proportional hazard model. 
